The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of ixabepilone and vorinostat in metastatic breast cancer.
Thehang H. Luu
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Onyx; Pfizer
Suzette Blanchard
No relevant relationships to disclose
Jan Hendrik Beumer
Research Funding - Bristol-Myers Squibb
Bean N. Anyang
Research Funding - Bristol-Myers Squibb
George Somlo
No relevant relationships to disclose
Joanne E. Mortimer
Research Funding - Cephalon; Pfizer
Arti Hurria
Consultant or Advisory Role - Amgen; Genentech; GTx
Research Funding - Abraxis BioScience; Celgene; GSU
Lixin Yang
No relevant relationships to disclose
Yun Yen
Research Funding - Bristol-Myers Squibb